Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.09%0700.HK-5.98%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.14%ORCL-0.97%3988.HK+0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.54%0857.HK-1.46%UNH-10.21%1288.HK-0.84%PM-0.85%0005.HK-1.74%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.64%AUDUSD-1.47%EURAUD+0.98%AUDCAD-0.98%AUDCHF-0.97%GBPAUD+0.90%AUDNZD-0.85%NZDJPY-0.81%GBPJPY-0.75%EURJPY-0.69%CHFJPY-0.67%CADJPY-0.67%NZDUSD-0.62%AUDSGD-0.59%GBPUSD-0.56%AUDDKK-0.54%USDCHF+0.54%USDCAD+0.51%EURUSD-0.50%AUDNOK-0.45%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDMXN+0.26%NZDMXN+0.23%USDZAR+0.22%USDTRY+0.21%USDJPY-0.19%USDTHB+0.19%EURZAR+0.16%USDILS+0.16%CHFNOK+0.14%NZDCAD-0.14%USDNOK+0.14%GBPZAR+0.12%USDCNH-0.12%EURNZD+0.12%NZDCHF-0.11%NOKJPY-0.11%USDPLN+0.10%CHFSEK+0.10%USDSEK+0.10%EURCNH-0.10%GBPSGD-0.09%EURNOK+0.08%GBPCAD-0.07%EURGBP+0.07%GBPNZD+0.06%PLNJPY-0.06%USDDKK+0.06%EURHKD-0.06%EURSGD-0.05%EURPLN+0.04%EURSEK+0.04%USDCOP-0.04%EURCZK+0.04%EURCHF+0.04%SGDJPY+0.03%GBPCHF-0.03%CADCHF+0.03%CHFSGD+0.02%USDSGD+0.01%NZDSGD0.00%USDHKD0.00%EURCAD0.00%EURDKK0.00%GAGUSD+0.96%XAGUSD+0.96%UKOIL+0.76%GAUUSD+0.70%XAUUSD+0.70%XNGUSD-0.67%USOIL+0.55%HG1+0.40%XPTUSD+0.36%W1-0.34%COTTON+0.24%C1-0.17%BTCUSD-3.21%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.99%XMRUSDT-1.44%DOGEUSD+55.95%LINKUSD-3.20%XLMUSD-3.70%BCHUSDT-3.45%LTCUSD+47.50%UNIUSD-2.53%SUIUSD-3.06%TONUSD+59.18%HBARUSDT-4.90%TAOUSDT-3.04%AAVEUSD-3.06%ONDOUSDT-5.06%ICPUSDT-2.40%DOTUSDT-3.76%WLDUSDT-3.20%ARBUSDT-4.92%ATOMUSDT-2.54%INJUSDT-6.97%STXUSDT-2.03%PYTHUSDT-0.67%TIAUSDT-3.65%FETUSDT-4.09%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.08%OPUSDT-2.63%IOTAUSDT-2.57%POLUSDT-1.70%WIFUSDT-2.25%AXSUSDT-2.47%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-5.93%GALAUSDT-2.38%DYDXUSDT-2.32%ORDIUSDT-2.71%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.09%0700.HK-5.98%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK+0.14%ORCL-0.97%3988.HK+0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.54%0857.HK-1.46%UNH-10.21%1288.HK-0.84%PM-0.85%0005.HK-1.74%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.64%AUDUSD-1.47%EURAUD+0.98%AUDCAD-0.98%AUDCHF-0.97%GBPAUD+0.90%AUDNZD-0.85%NZDJPY-0.81%GBPJPY-0.75%EURJPY-0.69%CHFJPY-0.67%CADJPY-0.67%NZDUSD-0.62%AUDSGD-0.59%GBPUSD-0.56%AUDDKK-0.54%USDCHF+0.54%USDCAD+0.51%EURUSD-0.50%AUDNOK-0.45%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDMXN+0.26%NZDMXN+0.23%USDZAR+0.22%USDTRY+0.21%USDJPY-0.19%USDTHB+0.19%EURZAR+0.16%USDILS+0.16%CHFNOK+0.14%NZDCAD-0.14%USDNOK+0.14%GBPZAR+0.12%USDCNH-0.12%EURNZD+0.12%NZDCHF-0.11%NOKJPY-0.11%USDPLN+0.10%CHFSEK+0.10%USDSEK+0.10%EURCNH-0.10%GBPSGD-0.09%EURNOK+0.08%GBPCAD-0.07%EURGBP+0.07%GBPNZD+0.06%PLNJPY-0.06%USDDKK+0.06%EURHKD-0.06%EURSGD-0.05%EURPLN+0.04%EURSEK+0.04%USDCOP-0.04%EURCZK+0.04%EURCHF+0.04%SGDJPY+0.03%GBPCHF-0.03%CADCHF+0.03%CHFSGD+0.02%USDSGD+0.01%NZDSGD0.00%USDHKD0.00%EURCAD0.00%EURDKK0.00%GAGUSD+0.96%XAGUSD+0.96%UKOIL+0.76%GAUUSD+0.70%XAUUSD+0.70%XNGUSD-0.67%USOIL+0.55%HG1+0.40%XPTUSD+0.36%W1-0.34%COTTON+0.24%C1-0.17%BTCUSD-3.21%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.99%XMRUSDT-1.44%DOGEUSD+55.95%LINKUSD-3.20%XLMUSD-3.70%BCHUSDT-3.45%LTCUSD+47.50%UNIUSD-2.53%SUIUSD-3.06%TONUSD+59.18%HBARUSDT-4.90%TAOUSDT-3.04%AAVEUSD-3.06%ONDOUSDT-5.06%ICPUSDT-2.40%DOTUSDT-3.76%WLDUSDT-3.20%ARBUSDT-4.92%ATOMUSDT-2.54%INJUSDT-6.97%STXUSDT-2.03%PYTHUSDT-0.67%TIAUSDT-3.65%FETUSDT-4.09%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.08%OPUSDT-2.63%IOTAUSDT-2.57%POLUSDT-1.70%WIFUSDT-2.25%AXSUSDT-2.47%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-5.93%GALAUSDT-2.38%DYDXUSDT-2.32%ORDIUSDT-2.71%NOTUSDT+0.86%RONINUSDT-2.92%
BI

Biogen Inc. (BIIB)

NASDAQ • Healthcare

$251.41
+$0.62 (+0.2%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$248.56
Day Range$247 - $252.79
Avg. Volume (3M)1.1M
Market Cap$37.1B
P/E Ratio106.5
52 Week Range
$160.36$261
Next EarningsIn 78 daysFeb 5, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$2.8B100%
Gross Profitminus cost of goods$2B73%
Operating Incomeminus R&D and overhead$128.4M5%

In plain terms: out of every $100 in revenue, Biogen Inc. currently loses $1.

Fundamentals & Financials

Revenue (TTM)
$10.2B
Net Income (TTM)
$347.5M
EPS (TTM)
$2.36
ROA (TTM)
1.08%
Current Ratio
1.95
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+17.0%Q2 2026$3.57
+22.4%Q3 2026$3.6
+31.7%Q4 2026$2.62
Next

Feb 5

in 78 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +31.7%

Biogen beat expectations on both the top and bottom line in the third fiscal quarter of 2026, based on preliminary results reported October 28, 2026, with revenue of $2.804 billion topping the $2.635 billion estimate (+6.4%) while adjusted EPS of $2.62 topped the $1.99 estimate (+31.7%). Revenue rose 14.2% to roughly $2.8 billion (up from $2.455 billion a year ago), alongside gross profit of about $2.1 billion and a gross margin of roughly 73%. Despite the revenue growth, adjusted EPS fell 45.5% year over year to $2.62 (down from $4.81 a year ago). The quarter generated operating cash flow of about $640.8 million. For the next period, consensus calls for EPS of $3.14 on revenue of $2.579 billion.

View full earnings history

About Biogen Inc.

Biogen Inc. develops, manufactures, and markets therapies for neurological, neurodegenerative, autoimmune, and blood-related diseases. Listed on NASDAQ as BIIB, the company sits within the healthcare sector as a branded drug maker, and it recorded $9.8 billion in revenue in FY2025.

Name
Biogen Inc.
CEO
Christopher A. Viehbacher
Industry
Healthcare
Year Founded
1978
Employees
7,500

Today's Snapshot

AI-generated

BIIB ended the day slightly higher at 251.41, while its sector was weaker. At the close, BIIB was within 3.7% of its 52-week high of 261.00. Biogen reported positive two-year results for diranersen, an experimental Alzheimer’s treatment.

Trading Volume

Above 10d avg 999.1K

1.1M

vs S&P 500 Today

Outperforming Market

+0.51%

Updated: November 18, 2026 at 21:20 UTC

Technical Indicators

5 Buy3 Neutral0 Sell
BIIB exhibits a constructive technical backdrop: the stock trades well above its 200-day averages and near short-term averages that are also positive, while ADX above the mid-20s signals a firming trend. Momentum readings are broadly neutral to mildly positive — RSI sits in the mid-50s and MACD is elevated — and volatility is contained with ATR under ten dollars as a percentage of price. Notably, on-balance volume is positive, suggesting institutional follow-through even though the classic pivot is merely neutral. Technical takeaway: Strong Buy — trend strength and supportive volume favor the higher-timeframe uptrend.
All signals
  • EMA (5 indicators)$209.54 - $251.15
    Buy
  • RSI (14)56.64
    Neutral
  • Stochastic %K (14, 3, 3)53.73
    Neutral
  • MACD Level (12, 26)4.59
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.